Population Pharmacokinetics and Exposure‐Response Modeling for Evinacumab in Children, Adolescents, and Adults With Homozygous Familial Hypercholesterolemia

ABSTRACT Evinacumab, an angiopoietin‐like 3 (ANGPTL3) inhibitor, significantly reduces low‐density lipoprotein cholesterol (LDL‐C), independent of low‐density lipoprotein receptor, in patients with homozygous familial hypercholesterolemia (HoFH). A population pharmacokinetic (PK)/pharmacodynamic (PD...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Sébastien Bihorel, Robert Dingman, Jeanne Mendell, Yuhuan Wang, Poulabi Banerjee, Robert Pordy, John D. Davis, A. Thomas DiCioccio, Lutz Harnisch
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Wiley 2025-11-01
coleção:	CPT: Pharmacometrics & Systems Pharmacology
Assuntos:	evinacumab exposure‐response homozygous familial hypercholesterolemia pediatrics pharmacokinetics
Acesso em linha:	https://doi.org/10.1002/psp4.70016
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!